Although not all promoter/enhancer fusions may result in chimeric transcripts, the effect of these fusions, for example, (over)expression of the 3′ fusion partner, is likely to manifest itself in the RNA-seq data, highlighting additional tests that could be developed: One could think of quality controls in the analysis pipeline to screen for potential fusion events that result in overexpression (eg, the ZCCHC8-ROS1 fusion, Fig 5C) or develop algorithms that classify tumor entities on the basis of their expression profiles. This evidence concerns the gene ROS1 and neoplasm.